Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics. This journal is © the Owner Societies 2016

## SUPPORTING INFORMATION

# Secondary brown carbon formation *via* the dicarbonyl imine pathway: nitrogen heterocycle formation and synergistic effects

Christopher J. Kampf<sup>1,2,\*</sup>, Alexander Filippi<sup>1,2</sup>, Christoph Zuth<sup>1</sup>, Thorsten Hoffmann<sup>1</sup>, Till Opatz<sup>3</sup>

<sup>1</sup>Johannes Gutenberg-Universität Mainz, Institut für Anorganische und Analytische Chemie,

Duesbergweg 10-14, 55128 Mainz, Germany

<sup>2</sup>Max-Planck-Institut für Chemie, Abteilung für Multiphasenchemie, Hahn-Meitner-Weg 1,

55128 Mainz, Germany

<sup>3</sup>Johannes Gutenberg-Universität Mainz, Institut für Organische Chemie, Duesbergweg 10-14, 55128 Mainz, Germany

\*address correspondence to: Christopher J. Kampf, phone: +49 6131 39 25877, fax: +49 6131 39 25336, Email: kampfc@uni-mainz.de


## **Summary**

Table S1		Page S2
Figures S1-S7	UV/Vis Spectrometry	Pages S3-S6
Figures S8-S15	HPLC-DAD analysis	Pages S7-S14
Figures S16-S32	UHPLC-HRMS <sup>2</sup> analysis	Pages S15-S21
Figures S33-S36	Reference compound analysis	Pages S22-S25


**Table S1**. List of initial and final pH, as well as m/z values for targeted MS2 analyses of reaction systems studied in this work.

Reaction system	initial pH	final pH	m/z for targeted MS <sup>2</sup>
Gly/AS	3.2-3.4	2.4-2.5	69.1. 115.1
MGly/AS	3.0-3.1	2.3	125.1, 126.1, 83.2, 251.1, 215.1
BD/AS	3.4-3.5	2.8	221.1, 195.1
AcAc/AS	4.0-4.2	3.7-3.9	
HD/AS	3.9-4.2	3.6-3.7	201.2, 280.3, 265.3, 187.2, 217.2, 96.14
GA/AS	3.4-3.6	2.3-2.5	214.2, 296.3, 82.2, 314.3
AcA+AcAc/AS	3.7-3.8	2.5-2.6	230.2, 209.2, 208.2, 164.2
Gly+AcAc/AS	3.3	1.7	140.2, 164.2, 69.1
Gly+MGly/AS	2.9	2.1	125.1, 168.1, 111.2, 115.2, 69.1, 257.1, 83.2, 234.2
Gly+MGly+GA/AS	2.8	1.9	125.1, 115.2, 214.2, 296.3, 225.2, 235.2, 153.2, 207.2, 167.2
Gly/glycine	3.9	3.4	185.1, 199.1, 143.1
MGly/glycine	3.5	2.9	184.1, 156.1
BD/glycine	4.9	3.9	254.1, 238.1, 213.1
HD/glycine	4.3	3.4	317.2, 381.3, 166.1, 454.3, 248.2, 307.3, 315.2, 344.3, 154.1
GA/glycine	3.5	3.3	138.1, 238.2, 340.3, 220.2, 152.0


# 1. UV/Vis Spectrometry




**Figure S1**. UV/Vis spectra of Gly/AS (top left), Gly/glycine (top right), MGly/AS (bottom left), and MGly/glycine (bottom right). Initial dicarbonyl concentrations were 1M, AS was 1M, and glycine was 0.5M.




**Figure S2**. UV/Vis spectra of BD/AS (top left), BD/glycine (top right), AcAc/AS (bottom left), and AcAc/glycine (bottom right). Initial dicarbonyl concentrations were 1M, AS was 1M, and glycine was 0.5M.




**Figure S3**. UV/Vis spectra of HD/AS (top left), HD/glycine (top right), GA/AS (bottom left), and GA/glycine (bottom right). Initial dicarbonyl concentrations were 1M, AS was 1M, and glycine was 0.5M.




**Figure S4**. UV/Vis spectra of AcA+AcAc/AS (top left), Gly+AcAc/AS (top right), Gly+MGly/AS (bottom left), and Gly+MGly+GA/AS (bottom right). Initial dicarbonyl and AS concentrations were 1M.



**Figure S5**. UV/Vis spectra of AcA/AS (top left), AcA/H<sub>2</sub>O (top right), Gly/H<sub>2</sub>O (bottom left), and MGly/H<sub>2</sub>O (bottom right). Initial dicarbonyl and AS concentrations were 1M.




**Figure S6**. UV/Vis spectra of  $BD/H_2O$  (top left),  $AcAc/H_2O$  (top right),  $HD/H_2O$  (bottom left), and  $GA/H_2O$  (bottom right). Initial dicarbonyl concentrations were 1M.



**Figure S7**. UV/Vis spectra of reference compounds in H<sub>2</sub>O: a) 1*H*-Imidazole (IM), b) 1*H*-Imidazole-2-carbaldehyde (IC), c) 3-Acetyl-2,4,6-trimethylpyridine, d) 3,5-Diacetyl-2,4,6-trimethyl-1,4-dihydropyridine.

## 2. HPLC-DAD analysis



**Figure S8** a) HPLC-DAD image plot for Gly/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for Gly/AS (bottom); b) HPLC-DAD image plot for Gly/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for Gly/glycine (bottom).







Figure S9 a) HPLC-DAD image plot for MGly/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda=300$  - 500 nm) for MGly/AS (bottom); b) HPLC-DAD image plot for MGly/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda=300$  - 500 nm) for MGly/glycine (bottom).




**Figure S10** a) HPLC-DAD image plot for BD/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for BD/AS (bottom); b) HPLC-DAD image plot for BD/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for BD/glycine (bottom).




**Figure S11** a) HPLC-DAD image plot for AcAc/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for AcAc/AS (bottom); b) HPLC-DAD image plot for AcAc/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for AcAc/glycine (bottom).



**Figure S12** a) HPLC-DAD image plot for HD/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for HD/AS (bottom); b) HPLC-DAD image plot for HD/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for HD/glycine (bottom).



**Figure S13** a) HPLC-DAD image plot for GA/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for GA/AS (bottom); b) HPLC-DAD image plot for GA/glycine: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for GA/glycine (bottom).



**Figure S14** a) HPLC-DAD image plot for AcA+AcAc/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for AcA+AcAc/AS (bottom); b) HPLC-DAD image plot for Gly+AcAc/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda = 300$  - 500 nm) for Gly+AcAc/AS (bottom).






Figure S15 a) HPLC-DAD image plot for Gly+MGly/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda=300$  - 500 nm) for Gly+MGly/AS (bottom); b) HPLC-DAD image plot for Gly+MGly+GA/AS: 0.5 (top) and 144 h (middle) reaction time; UV/Vis chromatogram (sum of  $\lambda=300$  - 500 nm) for Gly+MGly+GA/AS (bottom).


## 3. UHPLC-HESI-HRMS<sup>2</sup> analysis




**Figure S16** MS<sup>2</sup> spectra of products observed in Gly/AS: a) m/z 69.05 (HPLC RT = 1.2 min, UHPLC RT = 0.32 min), b) m/z 115.05 (HPLC RT = 1.1 min, UHPLC RT = 0.33 min). Spectra were acquired using a fragmentation energy of 70 NCE (instrument specific parameter).



**Figure S17** MS<sup>2</sup> spectrum of product observed in Gly/glycine: m/z 185.06 (HPLC RT = 1.1 min, UHPLC RT = 0.34 min). Spectra were acquired using a fragmentation energy of 70 NCE (instrument specific parameter).



**Figure S18** MS<sup>2</sup> spectra of products observed in MGly/AS: a) m/z 83.06 (HPLC RT = 1.2 min, UHPLC RT = 0.35 min) acquired using 70 NCE fragmentation energy (instrument specific parameter), b) m/z 125.07 (HPLC RT = 3.9 min, UHPLC RT = 0.64 min), c) m/z 251.10 (HPLC RT = 7.7 min, UHPLC RT = 1.75 min).



**Figure S19** MS<sup>2</sup> spectrum of product observed in MGly/glycine: m/z 184.06 (HPLC RT = 6.8 min, UHPLC RT = 1.56 min).







Figure S20 MS<sup>2</sup> spectrum of product observed in BD/AS: m/z 112.08 (HPLC RT = 7.8 min, UHPLC RT = 1.8 min).




**Figure S21** MS<sup>2</sup> spectrum of product observed in BD/glycine: m/z 254.10 (HPLC RT = 6.8 min, UHPLC RT = 1.48 min).



**Figure S22** MS<sup>2</sup> spectrum of product observed in AcAc/AS: m/z 164.10 (HPLC RT = 6.3 min, UHPLC RT = 0.64 min). Spectra were acquired using a fragmentation energy of 70 NCE (instrument specific parameter).



**Figure S23** MS<sup>2</sup> spectrum of product observed in AcAc/glycine: m/z 158.0817 (HPLC RT = 7.3 min, UHPLC RT = 1.34 min). Spectra were acquired using a fragmentation energy of 70 NCE (instrument specific parameter).



**Figure S24** MS<sup>2</sup> spectrum of product observed in HD/AS: m/z 201.14 (HPLC RT = 7.7 min, UHPLC RT = 1.83 min).







Figure S25 MS<sup>2</sup> spectra of products observed in HD/AS: m/z 187.12 (HPLC RT = 7.6 min, UHPLC RT = 1.76 min)




**Figure S26** MS<sup>2</sup> spectrum of product observed in HD/glycine: a) m/z 248.13 (HPLC RT = 6.9 min, UHPLC RT = 1.55 min); b) m/z 317.15 (HPLC RT = 7.1 min, UHPLC RT = 1.57 min).



**Figure S27** MS<sup>2</sup> spectrum of product observed in GA/AS: a) m/z 80.05 (HPLC RT = 0.9 min, UHPLC RT = 0.36 min).



**Figure S28** MS<sup>2</sup> spectrum of product observed in GA/glycine: m/z 138.05 (HPLC RT = 1.1 min, UHPLC RT = 0.36 min).



**Figure S29** MS<sup>2</sup> spectrum of product observed in AcAc+Gly/AS: m/z 140.07 (HPLC RT = 6.7 min, UHPLC RT = 1.51 min).






Figure S30 MS<sup>2</sup> spectrum of product observed in Gly+MGly/AS: m/z 111.06 (HPLC RT = 1.4 min, UHPLC RT = 0.37 min).




**Figure S31** MS<sup>2</sup> spectrum of product observed in Gly+MGly/AS: m/z 111.06 (HPLC RT = 2.5 min, UHPLC RT = 0.56 min).




**Figure S32** MS<sup>2</sup> spectrum of product observed in Gly+MGly+GA/AS: m/z 153.10 (HPLC RT = 3.5 min, UHPLC RT = 0.61 min).


## 4. Reference compound analysis




**Figure S33** 1*H*-imidazole (IM): reference compound a) UHPLC-MS EIC m/z 69.04-69.06, b) MS<sup>2</sup> of m/z 69.05; product in Gly/AS c) UHPLC-MS EIC m/z 69.04-69.06, d) MS<sup>2</sup> of m/z 69.05. MS<sup>2</sup> spectra were acquired using 70 NCE fragmentation energy (instrument specific parameter).



**Figure S34** 1*H*-imidazole-2-carbaldehyde (IC): reference compound a) UHPLC-MS EIC m/z 115.04-115.06, b) MS<sup>2</sup> of m/z 115.05; product in Gly/AS c) UHPLC-MS EIC m/z 115.04-115.06, d) MS<sup>2</sup> of m/z 115.05. MS<sup>2</sup> spectra were acquired using 70 NCE fragmentation energy (instrument specific parameter).



**Figure S35** 3-acetyl-2,4,6-trimethylpyridin (Pyr): reference compound a) UHPLC-MS EIC m/z 164.10-164.15, b) MS 0.65 min RT; product in AcAc/AS c) UHPLC-MS EIC m/z 164.10-164.15, d) MS at 0.64 min RT. No MS<sup>2</sup> spectra of m/z 164.1 were recorded.



**Figure S36** 3,5-diacetyl-2,4,6-trimethyl-1,4-dihydropyridin (DHP): reference compound a) UHPLC-MS EIC m/z 208.10-208.15, b) MS<sup>2</sup> of m/z 208.13; product in AA+AcAc/AS c) UHPLC-MS EIC m/z 208.10-208.15, d) MS<sup>2</sup> of m/z 208.13. MS<sup>2</sup> spectra were acquired using 70 NCE fragmentation energy (instrument specific parameter).